MovDisordV3, PascalFrancis, Corpus, bibRecord, 001B61

Epidemiology of tardive dyskinesia : Is risk declining with modern antipsychotics?

Identifieur interne : 001B61 ( PascalFrancis/Corpus ); précédent : 001B60; suivant : 001B62

Epidemiology of tardive dyskinesia : Is risk declining with modern antipsychotics?

Auteurs : Daniel Tarsy ; Ross J. Baldessarini

Source :

Movement disorders [ 0885-3185 ] ; 2006.

RBID : Pascal:06-0289023

Descripteurs français

Pascal (Inist)
- Système nerveux pathologie, Dyskinésie, Extrapyramidal syndrome, Epidémiologie, Facteur risque, Antipsychotique, Neuroleptique.

English descriptors

KwdEn :
- Antipsychotic, Dyskinesia, Epidemiology, Extrapyramidal syndrome, Nervous system diseases, Neuroleptic, Risk factor.

Abstract

Second-generation antipsychotic drugs (APDs), including aripiprazole, clozapine, olanzapine, risperidone, quetiapine, and ziprasidone dominate outpatient and inpatient clinical practice, having largely displaced the older neuroleptics. Modern APDs have relatively low risk for acute extrapyramidal syndromes characteristic of older neuroleptics, particularly acute dystonia and Parkinsonism, with variable risks of akathisia and the rare neuroleptic malignant syndrome. Anticipated reduction in risk of tardive dyskinesia (TD) is less well documented. Nearly 50 years after initial reports on TD, it is appropriate to reexamine the epidemiology of this potentially severe late adverse effect of long-term APD treatment in light of current research and practice. We compared recent estimates of incidence and prevalence of TD identified with some modern APDs to the epidemiology of TD in the earlier neuroleptic era. Such comparisons are confounded by complex modem APD regimens, uncommon exposure limited to a single modern APD, effects of previous exposure to typical neuroleptics, and neurological assessments that are rarely prospective or systematic. Available evidence suggests that the risk of TD may be declining, but longitudinal studies of patients never treated with traditional neuroleptics and exposed to only a single modern APD are required to quantify TD risks with specific drugs. Long-term use of APDs should continue to be based on research-supported indications, with regular specific examination for emerging TD.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 21`
A06				`@2 5`
A08	`01`	`1`	`ENG`	`@1 Epidemiology of tardive dyskinesia : Is risk declining with modern antipsychotics?`
A11	`01`	`1`		`@1 TARSY (Daniel)`
A11	`02`	`1`		`@1 BALDESSARINI (Ross J.)`
A14	`01`			`@1 Department of Neurology, Harvard Medical School @2 Boston, Massachusetts @3 USA @Z 1 aut.`
A14	`02`			`@1 Parkinson's Disease and Movement Disorders Center, Beth Israel-Deaconess Medical Center @2 Boston, Massachusetts @3 USA @Z 1 aut.`
A14	`03`			`@1 Department of Psychiatry, Harvard Medical School @2 Boston, Massachusetts @3 USA @Z 2 aut.`
A14	`04`			`@1 Psychopharmacology Program, McLean Division of Massachusetts General Hospital @2 Boston, Massachusetts @3 USA @Z 2 aut.`
A20				`@1 589-598`
A21				`@1 2006`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000142568210010`
A44				`@0 0000 @1 © 2006 INIST-CNRS. All rights reserved.`
A45				`@0 117 ref.`
A47	`01`	`1`		`@0 06-0289023`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Second-generation antipsychotic drugs (APDs), including aripiprazole, clozapine, olanzapine, risperidone, quetiapine, and ziprasidone dominate outpatient and inpatient clinical practice, having largely displaced the older neuroleptics. Modern APDs have relatively low risk for acute extrapyramidal syndromes characteristic of older neuroleptics, particularly acute dystonia and Parkinsonism, with variable risks of akathisia and the rare neuroleptic malignant syndrome. Anticipated reduction in risk of tardive dyskinesia (TD) is less well documented. Nearly 50 years after initial reports on TD, it is appropriate to reexamine the epidemiology of this potentially severe late adverse effect of long-term APD treatment in light of current research and practice. We compared recent estimates of incidence and prevalence of TD identified with some modern APDs to the epidemiology of TD in the earlier neuroleptic era. Such comparisons are confounded by complex modem APD regimens, uncommon exposure limited to a single modern APD, effects of previous exposure to typical neuroleptics, and neurological assessments that are rarely prospective or systematic. Available evidence suggests that the risk of TD may be declining, but longitudinal studies of patients never treated with traditional neuroleptics and exposed to only a single modern APD are required to quantify TD risks with specific drugs. Long-term use of APDs should continue to be based on research-supported indications, with regular specific examination for emerging TD.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B02U01`
C02	`03`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Système nerveux pathologie @5 01`
C03	`01`	`X`	`ENG`	`@0 Nervous system diseases @5 01`
C03	`01`	`X`	`SPA`	`@0 Sistema nervioso patología @5 01`
C03	`02`	`X`	`FRE`	`@0 Dyskinésie @5 02`
C03	`02`	`X`	`ENG`	`@0 Dyskinesia @5 02`
C03	`02`	`X`	`SPA`	`@0 Disquinesia @5 02`
C03	`03`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 03`
C03	`03`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 03`
C03	`03`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 03`
C03	`04`	`X`	`FRE`	`@0 Epidémiologie @5 09`
C03	`04`	`X`	`ENG`	`@0 Epidemiology @5 09`
C03	`04`	`X`	`SPA`	`@0 Epidemiología @5 09`
C03	`05`	`X`	`FRE`	`@0 Facteur risque @5 10`
C03	`05`	`X`	`ENG`	`@0 Risk factor @5 10`
C03	`05`	`X`	`SPA`	`@0 Factor riesgo @5 10`
C03	`06`	`X`	`FRE`	`@0 Antipsychotique @5 11`
C03	`06`	`X`	`ENG`	`@0 Antipsychotic @5 11`
C03	`06`	`X`	`SPA`	`@0 Antipsicótico @5 11`
C03	`07`	`X`	`FRE`	`@0 Neuroleptique @5 12`
C03	`07`	`X`	`ENG`	`@0 Neuroleptic @5 12`
C03	`07`	`X`	`SPA`	`@0 Neuroléptico @5 12`
C07	`01`	`X`	`FRE`	`@0 Mouvement involontaire @5 37`
C07	`01`	`X`	`ENG`	`@0 Involuntary movement @5 37`
C07	`01`	`X`	`SPA`	`@0 Movimiento involuntario @5 37`
C07	`02`	`X`	`FRE`	`@0 Trouble neurologique @5 38`
C07	`02`	`X`	`ENG`	`@0 Neurological disorder @5 38`
C07	`02`	`X`	`SPA`	`@0 Trastorno neurológico @5 38`
C07	`03`	`X`	`FRE`	`@0 Encéphale pathologie @5 39`
C07	`03`	`X`	`ENG`	`@0 Cerebral disorder @5 39`
C07	`03`	`X`	`SPA`	`@0 Encéfalo patología @5 39`
C07	`04`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 40`
C07	`04`	`X`	`ENG`	`@0 Central nervous system disease @5 40`
C07	`04`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 40`
N21				`@1 184`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 06-0289023 INIST
ET :	Epidemiology of tardive dyskinesia : Is risk declining with modern antipsychotics?
AU :	TARSY (Daniel); BALDESSARINI (Ross J.)
AF :	Department of Neurology, Harvard Medical School/Boston, Massachusetts/Etats-Unis (1 aut.); Parkinson's Disease and Movement Disorders Center, Beth Israel-Deaconess Medical Center/Boston, Massachusetts/Etats-Unis (1 aut.); Department of Psychiatry, Harvard Medical School/Boston, Massachusetts/Etats-Unis (2 aut.); Psychopharmacology Program, McLean Division of Massachusetts General Hospital/Boston, Massachusetts/Etats-Unis (2 aut.)
DT :	Publication en série; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2006; Vol. 21; No. 5; Pp. 589-598; Bibl. 117 ref.
LA :	Anglais
EA :	Second-generation antipsychotic drugs (APDs), including aripiprazole, clozapine, olanzapine, risperidone, quetiapine, and ziprasidone dominate outpatient and inpatient clinical practice, having largely displaced the older neuroleptics. Modern APDs have relatively low risk for acute extrapyramidal syndromes characteristic of older neuroleptics, particularly acute dystonia and Parkinsonism, with variable risks of akathisia and the rare neuroleptic malignant syndrome. Anticipated reduction in risk of tardive dyskinesia (TD) is less well documented. Nearly 50 years after initial reports on TD, it is appropriate to reexamine the epidemiology of this potentially severe late adverse effect of long-term APD treatment in light of current research and practice. We compared recent estimates of incidence and prevalence of TD identified with some modern APDs to the epidemiology of TD in the earlier neuroleptic era. Such comparisons are confounded by complex modem APD regimens, uncommon exposure limited to a single modern APD, effects of previous exposure to typical neuroleptics, and neurological assessments that are rarely prospective or systematic. Available evidence suggests that the risk of TD may be declining, but longitudinal studies of patients never treated with traditional neuroleptics and exposed to only a single modern APD are required to quantify TD risks with specific drugs. Long-term use of APDs should continue to be based on research-supported indications, with regular specific examination for emerging TD.
CC :	002B17; 002B02U01; 002B17G
FD :	Système nerveux pathologie; Dyskinésie; Extrapyramidal syndrome; Epidémiologie; Facteur risque; Antipsychotique; Neuroleptique
FG :	Mouvement involontaire; Trouble neurologique; Encéphale pathologie; Système nerveux central pathologie
ED :	Nervous system diseases; Dyskinesia; Extrapyramidal syndrome; Epidemiology; Risk factor; Antipsychotic; Neuroleptic
EG :	Involuntary movement; Neurological disorder; Cerebral disorder; Central nervous system disease
SD :	Sistema nervioso patología; Disquinesia; Extrapiramidal síndrome; Epidemiología; Factor riesgo; Antipsicótico; Neuroléptico
LO :	INIST-20953.354000142568210010
ID :	06-0289023

Links to Exploration step

Pascal:06-0289023

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Epidemiology of tardive dyskinesia : Is risk declining with modern antipsychotics?</title>
<author><name sortKey="Tarsy, Daniel" sort="Tarsy, Daniel" uniqKey="Tarsy D" first="Daniel" last="Tarsy">Daniel Tarsy</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Harvard Medical School</s1>
<s2>Boston, Massachusetts</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Parkinson's Disease and Movement Disorders Center, Beth Israel-Deaconess Medical Center</s1>
<s2>Boston, Massachusetts</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Baldessarini, Ross J" sort="Baldessarini, Ross J" uniqKey="Baldessarini R" first="Ross J." last="Baldessarini">Ross J. Baldessarini</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Psychiatry, Harvard Medical School</s1>
<s2>Boston, Massachusetts</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>Psychopharmacology Program, McLean Division of Massachusetts General Hospital</s1>
<s2>Boston, Massachusetts</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">06-0289023</idno>
<date when="2006">2006</date>
<idno type="stanalyst">PASCAL 06-0289023 INIST</idno>
<idno type="RBID">Pascal:06-0289023</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001B61</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Epidemiology of tardive dyskinesia : Is risk declining with modern antipsychotics?</title>
<author><name sortKey="Tarsy, Daniel" sort="Tarsy, Daniel" uniqKey="Tarsy D" first="Daniel" last="Tarsy">Daniel Tarsy</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Harvard Medical School</s1>
<s2>Boston, Massachusetts</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Parkinson's Disease and Movement Disorders Center, Beth Israel-Deaconess Medical Center</s1>
<s2>Boston, Massachusetts</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Baldessarini, Ross J" sort="Baldessarini, Ross J" uniqKey="Baldessarini R" first="Ross J." last="Baldessarini">Ross J. Baldessarini</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Psychiatry, Harvard Medical School</s1>
<s2>Boston, Massachusetts</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>Psychopharmacology Program, McLean Division of Massachusetts General Hospital</s1>
<s2>Boston, Massachusetts</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2006">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antipsychotic</term>
<term>Dyskinesia</term>
<term>Epidemiology</term>
<term>Extrapyramidal syndrome</term>
<term>Nervous system diseases</term>
<term>Neuroleptic</term>
<term>Risk factor</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term>
<term>Dyskinésie</term>
<term>Extrapyramidal syndrome</term>
<term>Epidémiologie</term>
<term>Facteur risque</term>
<term>Antipsychotique</term>
<term>Neuroleptique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Second-generation antipsychotic drugs (APDs), including aripiprazole, clozapine, olanzapine, risperidone, quetiapine, and ziprasidone dominate outpatient and inpatient clinical practice, having largely displaced the older neuroleptics. Modern APDs have relatively low risk for acute extrapyramidal syndromes characteristic of older neuroleptics, particularly acute dystonia and Parkinsonism, with variable risks of akathisia and the rare neuroleptic malignant syndrome. Anticipated reduction in risk of tardive dyskinesia (TD) is less well documented. Nearly 50 years after initial reports on TD, it is appropriate to reexamine the epidemiology of this potentially severe late adverse effect of long-term APD treatment in light of current research and practice. We compared recent estimates of incidence and prevalence of TD identified with some modern APDs to the epidemiology of TD in the earlier neuroleptic era. Such comparisons are confounded by complex modem APD regimens, uncommon exposure limited to a single modern APD, effects of previous exposure to typical neuroleptics, and neurological assessments that are rarely prospective or systematic. Available evidence suggests that the risk of TD may be declining, but longitudinal studies of patients never treated with traditional neuroleptics and exposed to only a single modern APD are required to quantify TD risks with specific drugs. Long-term use of APDs should continue to be based on research-supported indications, with regular specific examination for emerging TD.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>21</s2>
</fA05>
<fA06><s2>5</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Epidemiology of tardive dyskinesia : Is risk declining with modern antipsychotics?</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>TARSY (Daniel)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>BALDESSARINI (Ross J.)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Neurology, Harvard Medical School</s1>
<s2>Boston, Massachusetts</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Parkinson's Disease and Movement Disorders Center, Beth Israel-Deaconess Medical Center</s1>
<s2>Boston, Massachusetts</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Psychiatry, Harvard Medical School</s1>
<s2>Boston, Massachusetts</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Psychopharmacology Program, McLean Division of Massachusetts General Hospital</s1>
<s2>Boston, Massachusetts</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA20><s1>589-598</s1>
</fA20>
<fA21><s1>2006</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000142568210010</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2006 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>117 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>06-0289023</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Second-generation antipsychotic drugs (APDs), including aripiprazole, clozapine, olanzapine, risperidone, quetiapine, and ziprasidone dominate outpatient and inpatient clinical practice, having largely displaced the older neuroleptics. Modern APDs have relatively low risk for acute extrapyramidal syndromes characteristic of older neuroleptics, particularly acute dystonia and Parkinsonism, with variable risks of akathisia and the rare neuroleptic malignant syndrome. Anticipated reduction in risk of tardive dyskinesia (TD) is less well documented. Nearly 50 years after initial reports on TD, it is appropriate to reexamine the epidemiology of this potentially severe late adverse effect of long-term APD treatment in light of current research and practice. We compared recent estimates of incidence and prevalence of TD identified with some modern APDs to the epidemiology of TD in the earlier neuroleptic era. Such comparisons are confounded by complex modem APD regimens, uncommon exposure limited to a single modern APD, effects of previous exposure to typical neuroleptics, and neurological assessments that are rarely prospective or systematic. Available evidence suggests that the risk of TD may be declining, but longitudinal studies of patients never treated with traditional neuroleptics and exposed to only a single modern APD are required to quantify TD risks with specific drugs. Long-term use of APDs should continue to be based on research-supported indications, with regular specific examination for emerging TD.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B02U01</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Dyskinésie</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Dyskinesia</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Disquinesia</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Epidémiologie</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Epidemiology</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Epidemiología</s0>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Facteur risque</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Risk factor</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Factor riesgo</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Antipsychotique</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Antipsychotic</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Antipsicótico</s0>
<s5>11</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Neuroleptique</s0>
<s5>12</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Neuroleptic</s0>
<s5>12</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Neuroléptico</s0>
<s5>12</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Mouvement involontaire</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Involuntary movement</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Movimiento involuntario</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Trouble neurologique</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Neurological disorder</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Trastorno neurológico</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>40</s5>
</fC07>
<fN21><s1>184</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 06-0289023 INIST</NO>
<ET>Epidemiology of tardive dyskinesia : Is risk declining with modern antipsychotics?</ET>
<AU>TARSY (Daniel); BALDESSARINI (Ross J.)</AU>
<AF>Department of Neurology, Harvard Medical School/Boston, Massachusetts/Etats-Unis (1 aut.); Parkinson's Disease and Movement Disorders Center, Beth Israel-Deaconess Medical Center/Boston, Massachusetts/Etats-Unis (1 aut.); Department of Psychiatry, Harvard Medical School/Boston, Massachusetts/Etats-Unis (2 aut.); Psychopharmacology Program, McLean Division of Massachusetts General Hospital/Boston, Massachusetts/Etats-Unis (2 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2006; Vol. 21; No. 5; Pp. 589-598; Bibl. 117 ref.</SO>
<LA>Anglais</LA>
<EA>Second-generation antipsychotic drugs (APDs), including aripiprazole, clozapine, olanzapine, risperidone, quetiapine, and ziprasidone dominate outpatient and inpatient clinical practice, having largely displaced the older neuroleptics. Modern APDs have relatively low risk for acute extrapyramidal syndromes characteristic of older neuroleptics, particularly acute dystonia and Parkinsonism, with variable risks of akathisia and the rare neuroleptic malignant syndrome. Anticipated reduction in risk of tardive dyskinesia (TD) is less well documented. Nearly 50 years after initial reports on TD, it is appropriate to reexamine the epidemiology of this potentially severe late adverse effect of long-term APD treatment in light of current research and practice. We compared recent estimates of incidence and prevalence of TD identified with some modern APDs to the epidemiology of TD in the earlier neuroleptic era. Such comparisons are confounded by complex modem APD regimens, uncommon exposure limited to a single modern APD, effects of previous exposure to typical neuroleptics, and neurological assessments that are rarely prospective or systematic. Available evidence suggests that the risk of TD may be declining, but longitudinal studies of patients never treated with traditional neuroleptics and exposed to only a single modern APD are required to quantify TD risks with specific drugs. Long-term use of APDs should continue to be based on research-supported indications, with regular specific examination for emerging TD.</EA>
<CC>002B17; 002B02U01; 002B17G</CC>
<FD>Système nerveux pathologie; Dyskinésie; Extrapyramidal syndrome; Epidémiologie; Facteur risque; Antipsychotique; Neuroleptique</FD>
<FG>Mouvement involontaire; Trouble neurologique; Encéphale pathologie; Système nerveux central pathologie</FG>
<ED>Nervous system diseases; Dyskinesia; Extrapyramidal syndrome; Epidemiology; Risk factor; Antipsychotic; Neuroleptic</ED>
<EG>Involuntary movement; Neurological disorder; Cerebral disorder; Central nervous system disease</EG>
<SD>Sistema nervioso patología; Disquinesia; Extrapiramidal síndrome; Epidemiología; Factor riesgo; Antipsicótico; Neuroléptico</SD>
<LO>INIST-20953.354000142568210010</LO>
<ID>06-0289023</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001B61 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 001B61 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:06-0289023
   |texte=   Epidemiology of tardive dyskinesia : Is risk declining with modern antipsychotics?
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Epidemiology of tardive dyskinesia : Is risk declining with modern antipsychotics?

Epidemiology of tardive dyskinesia : Is risk declining with modern antipsychotics?

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri